The effect of human chorionic gonadotrophin contained in human menopausal gonadotropin on the clinical outcomes during progestin-primed ovarian stimulation
PDF | HTML | How to cite
Metrics: PDF 1511 views | HTML 2651 views | ?
Xiuxian Zhu1,*, Jing Ye1,*, Yonglun Fu1, Ai Ai1, Renfei Cai1, Yun Wang1, Qingging Hong1, Tian Hui1, Qifeng Lyu1, Qiuju Chen1 and Yanping Kuang1
1Department of Assisted Reproduction, Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, P.R. China
*These authors have contributed equally to this work
Yanping Kuang, email: [email protected]
Qiuju Chen, email: [email protected]
Keywords: human menopausal gonadotropin, human chorionic gonadotropin, follicle stimulation hormone, progestin-primed ovarian stimulation, beta human chronic gonadtropin
Received: March 29, 2017 Accepted: August 07, 2017 Published: August 24, 2017
Progestin-primed ovarian stimulation (PPOS) protocol has recently been demonstrated to be an novel regimen for preventing premature LH surges during controlled ovarian hyperstimulation (COH) in combination with frozen-thawed embryo transfer (FET). Our prospective controlled study was to explore the effect of human chorionic gonadotropin (hCG) contained in human menopausal gonadotropin (hMG) on the clinical outcomes in normalovulatory women undergoing COH with PPOS. A total of 180 patients were allocated into three groups according to the gonadotropin (Gn) used: group A (human menopausal gonadotropin, hMG-A), group B (hMG-B) or group C (follicle stimulating hormone, FSH). The primary outcome measured was the number of oocytes retrieved. The number of oocytes retrieved in group A B C was 10.72±5.78 11.33±5.19and13.38±8.97, respectively, with no statistic significance (p>0.05). Other embryological indicators were also similar (p>0.05). The concentration of serum and urinary β-hCG on the trigger day in group A and B were not associated with embryo results (p>0.05). There was no significant differences in the clinical pregnancy rate (41.67% vs. 51.56% vs. 39.51%, p>0.05) and implantation rate (31.58%vs. 34.75%vs.25.33%) after FET among the three groups. Thus the clinical characteristics were not affected by the hCG contained in hMG in normalovulatory women treated with PPOS.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.